# APRIL (AbatacePt in Rheumatoid Arthritis-ILD)

> **NCT03084419** · PHASE2 · UNKNOWN · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 30 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Interstitial Lung Disease

## Interventions

- **DRUG:** Abatacept

## Key facts

- **NCT ID:** NCT03084419
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-26
- **Primary completion:** 2020-03-01
- **Final completion:** 2020-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03084419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03084419, "APRIL (AbatacePt in Rheumatoid Arthritis-ILD)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03084419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*